N/A; see section 7002 for details regarding the implementation of a biosimilars pathway.
On Mar. 11, a HRSA-sponsored webinar (archived here) addressed program integrity and compliance best practices in contract pharmacy arrangements. On Mar. 24, HRSA, HHS OIG and GAO testified at a House Energy and Commerce Subcommittee hearing on the 340B Drug Pricing Program.
SEC. 7001. SHORT TITLE. (a) IN GENERAL.
—This subtitle may be cited as the ‘‘Biologics Price Competition and Innovation Act of 2009’’. (b) SENSE OF THE SENATE.—It is the sense of the Senate that a biosimilars pathway balancing innovation and consumer interests should be established.